Opening a new door to discovery, ROSALIND now empowers scientists to explore experiment results by key terms (Pathways, Signatures, Diseases and Drugs) that are significantly enriched across all samples using GSVA scores. You can access Term Exploration within the Discovery and Analysis section of each experiment. ROSALIND has been pre-computing these scores for the past several months, so many existing experiments already have this new analysis ready for exploration.

Every experiment and scientific question seeks to find insights on biological processes and pathways. Prior to now, this scientific journey always began with an exploration of genes to uncover the changes to underlying pathways. Now, you can begin exploring Pathways and significant Terms regardless of comparisons or cut-offs.

GSVA_Fast_3

Gene Set Variation Analysis (GSVA) estimates the variation of pathway activity over a sample population in an unsupervised manner and determines the sample-wise enrichment scores as a function of genes inside and outside of the gene set in comparison to the background. Every sample is calculated independently enabling exploration of significant terms across samples and is well suited for pathway-centric models, such as pathway activity identification or survival prediction.

This is just the beginning. We will be releasing additional Term Exploration features in the coming week. Please share your feedback to inspire@rosalind.bio and let us know what you think!

Related Posts

Tim Wesselman

Written by Tim Wesselman

Tim Wesselman is Founder of ROSALIND (formerly OnRamp BioInformatics) and CEO since 2013. For the 20 years prior to starting OnRamp, Tim had been dedicated to understanding next-generation servers and storage solutions. Serving as Vice President at Hewlett-Packard, he led strategy & partnerships with the market leaders in big data software, advanced processors and cloud computing. These partners included known names, like FaceBook, MapR, Cloudera and DataStax with solutions that companies like Apple, Amazon, Microsoft, Baidu and many others heavily rely on today. Seeing the opportunity to bring this knowledge of advanced computing technology into the healthcare space, Tim founded OnRamp and launched ROSALIND to empower researchers, doctors and drug developers to accelerate genomic discoveries through collaboration so that we all can realize the promise of precision medicine and unlock biology's greatest unknowns.